Literature DB >> 11099047

Deacetylation of p53 modulates its effect on cell growth and apoptosis.

J Luo1, F Su, D Chen, A Shiloh, W Gu.   

Abstract

The p53 tumour suppressor is a transcriptional factor whose activity is modulated by protein stability and post-translational modifications including acetylation. The mechanism by which acetylated p53 is maintained in vivo remains unclear. Here we show that the deacetylation of p53 is mediated by an histone deacetylase-1 (HDAC1)-containing complex. We have also purified a p53 target protein in the deacetylase complexes (designated PID; but identical to metastasis-associated protein 2 (MTA2)), which has been identified as a component of the NuRD complex. PID specifically interacts with p53 both in vitro and in vivo, and its expression reduces significantly the steady-state levels of acetylated p53. PID expression strongly represses p53-dependent transcriptional activation, and, notably, it modulates p53-mediated cell growth arrest and apoptosis. These results show that deacetylation and functional interactions by the PID/MTA2-associated NuRD complex may represent an important pathway to regulate p53 function.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11099047     DOI: 10.1038/35042612

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  299 in total

Review 1.  DNA replication blockade impairs p53-transactivation.

Authors:  R Takimoto; W S El-Deiry
Journal:  Proc Natl Acad Sci U S A       Date:  2001-01-30       Impact factor: 11.205

2.  The MeCP1 complex represses transcription through preferential binding, remodeling, and deacetylating methylated nucleosomes.

Authors:  Q Feng; Y Zhang
Journal:  Genes Dev       Date:  2001-04-01       Impact factor: 11.361

3.  Mi2, an auto-antigen for dermatomyositis, is an ATP-dependent nucleosome remodeling factor.

Authors:  H B Wang; Y Zhang
Journal:  Nucleic Acids Res       Date:  2001-06-15       Impact factor: 16.971

4.  Targeting protein inactivation through an oligomerization chain reaction.

Authors:  Francesco Contegno; Mario Cioce; Pier Giuseppe Pelicci; Saverio Minucci
Journal:  Proc Natl Acad Sci U S A       Date:  2002-02-12       Impact factor: 11.205

5.  Expression of SIRT1 is associated with lymph node metastasis and poor prognosis in both operable triple-negative and non-triple-negative breast cancer.

Authors:  Minqing Wu; Weidong Wei; Xiangsheng Xiao; Jiaoli Guo; Xinhua Xie; Laisheng Li; Yanan Kong; Ning Lv; Weihua Jia; Yin Zhang; Xiaoming Xie
Journal:  Med Oncol       Date:  2012-06-04       Impact factor: 3.064

Review 6.  Role of MTA2 in human cancer.

Authors:  Kyle R Covington; Suzanne A W Fuqua
Journal:  Cancer Metastasis Rev       Date:  2014-12       Impact factor: 9.264

7.  HDAC8 Inhibition Specifically Targets Inv(16) Acute Myeloid Leukemic Stem Cells by Restoring p53 Acetylation.

Authors:  Jing Qi; Sandeep Singh; Wei-Kai Hua; Qi Cai; Shi-Wei Chao; Ling Li; Hongjun Liu; Yinwei Ho; Tinisha McDonald; Allen Lin; Guido Marcucci; Ravi Bhatia; Wei-Jan Huang; Chung-I Chang; Ya-Huei Kuo
Journal:  Cell Stem Cell       Date:  2015-09-18       Impact factor: 24.633

Review 8.  Histone deacetylase inhibitors interact synergistically with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) to induce apoptosis in carcinoma cell lines.

Authors:  Jürgen Sonnemann; Jennifer Gänge; K Saravana Kumar; Cornelia Müller; Peter Bader; James F Beck
Journal:  Invest New Drugs       Date:  2005-03       Impact factor: 3.850

9.  Transcription factor interactions and chromatin modifications associated with p53-mediated, developmental repression of the alpha-fetoprotein gene.

Authors:  Thi T Nguyen; Kyucheol Cho; Sabrina A Stratton; Michelle Craig Barton
Journal:  Mol Cell Biol       Date:  2005-03       Impact factor: 4.272

10.  Histone deacetylase 3 suppresses Erk phosphorylation and matrix metalloproteinase (Mmp)-13 activity in chondrocytes.

Authors:  Lomeli R Carpio; Elizabeth W Bradley; Jennifer J Westendorf
Journal:  Connect Tissue Res       Date:  2016-09-23       Impact factor: 3.417

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.